- Defence Therapeutics (OTCQB:DTCFF) Wednesday said that FMS Consult GmbH, a European corporate financing consulting firm, was commissioned by Defence to execute on a financing strategy for the company and support pipeline growth.
- "Defence's lead technology, the Accum platform, has proven to be a broad and effective cancer killing technology for multiple indications and applications including ADCs, cancer vaccines and anti-cancer injectable drugs," Sebastien Plouffe, CEO and president of Defence said.
- Source: Press Release
Defence Therapeutics signs FMS Consult GmbH for financing strategy
Recommended For You
More Trending News
About DTCFF Stock
Related Stocks
| Symbol | Last Price | % Chg |
|---|---|---|
| DTCFF | - | - |
| Defence Therapeutics Inc. | ||